A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. (ARGiNAUT)

June 24, 2026 updated by: AstraZeneca

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)

This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.

Study Overview

Status

Recruiting

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Intervention / Treatment

Detailed Description

This is a Phase IIb, randomized, placebo-controlled, double-blind, parallel-group 24-week study to assess the efficacy, safety and tolerability of three doses of AZD8965 versus placebo administered to participants with IPF. The enrolled participants will include those on stable dose(s) of one or two approved antifibrotic therapies and those who are not taking any antifibrotic therapy. Approximately 360 participants will be randomized across approximately 200 sites globally.

Study Type

Interventional

Enrollment (Estimated)

359

Phase

Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: AstraZeneca Clinical Study Information Center
Phone Number: 1-877-240-9479
Email: information.center@astrazeneca.com

Study Locations

Argentina
- - Alberdi, Argentina, X5033DCE
    - Not yet recruiting
    - Research Site
  - Buenos Aires, Argentina, 1425
    - Not yet recruiting
    - Research Site
  - Ciudad de Buenos Aires, Argentina, C1414AIF
    - Not yet recruiting
    - Research Site
  - Florida, Argentina, B1602DQD
    - Not yet recruiting
    - Research Site
  - Rosario, Argentina, 2000
    - Withdrawn
    - Research Site
  - San Fernando, Argentina, B1646EBJ
    - Not yet recruiting
    - Research Site
Australia
- - Port Macquarie, Australia, 2444
    - Not yet recruiting
    - Research Site
  - Wollongong, Australia, 2500
    - Not yet recruiting
    - Research Site
Bulgaria
- - Haskovo, Bulgaria, 6300
    - Not yet recruiting
    - Research Site
  - Plovdiv, Bulgaria, 4001
    - Not yet recruiting
    - Research Site
  - Rousse, Bulgaria, 7000
    - Not yet recruiting
    - Research Site
  - Sofia, Bulgaria, 1618
    - Not yet recruiting
    - Research Site
  - Sofia, Bulgaria, 1680
    - Not yet recruiting
    - Research Site
  - Sofia, Bulgaria, 1756
    - Not yet recruiting
    - Research Site
Canada
- Alberta
  - Sherwood Park, Alberta, Canada, T8H 2M7
    - Not yet recruiting
    - Research Site
- British Columbia
  - Vancouver, British Columbia, Canada, V5Z 1M9
    - Not yet recruiting
    - Research Site
- Ontario
  - Ajax, Ontario, Canada, L1S 2J5
    - Recruiting
    - Research Site
  - Burlington, Ontario, Canada, L7N 3V2
    - Not yet recruiting
    - Research Site
  - Kingston, Ontario, Canada, K7M 4E7
    - Recruiting
    - Research Site
  - North York, Ontario, Canada, M2K 1E1
    - Not yet recruiting
    - Research Site
- Quebec
  - Saint-Charles-Borromée, Quebec, Canada, J6E 2B4
    - Not yet recruiting
    - Research Site
  - Sherbrooke, Quebec, Canada, J1H 5N4
    - Not yet recruiting
    - Research Site
Chile
- - Providencia, Chile, 7500504
    - Not yet recruiting
    - Research Site
  - Santiago, Chile, 7750495
    - Not yet recruiting
    - Research Site
  - Talca, Chile, 3481349
    - Not yet recruiting
    - Research Site
  - Viña del Mar, Chile, 2540488
    - Not yet recruiting
    - Research Site
  - Viña del Mar, Chile, 2531172
    - Not yet recruiting
    - Research Site
China
- - Beijing, China, 100730
    - Not yet recruiting
    - Research Site
  - Beijing, China, 100029
    - Not yet recruiting
    - Research Site
  - Beijing, China, 100000
    - Not yet recruiting
    - Research Site
  - Changchun, China, 130041
    - Not yet recruiting
    - Research Site
  - Changsha, China, 430033
    - Not yet recruiting
    - Research Site
  - Chengdu, China, 610041
    - Not yet recruiting
    - Research Site
  - Chengdu, China, 610078
    - Not yet recruiting
    - Research Site
  - Guangzhou, China, 510735
    - Not yet recruiting
    - Research Site
  - Lanzhou, China, 730030
    - Not yet recruiting
    - Research Site
  - Nanchang, China, 330000
    - Not yet recruiting
    - Research Site
  - Nanjing, China, 2100008
    - Not yet recruiting
    - Research Site
  - Shanghai, China, 200433
    - Not yet recruiting
    - Research Site
  - Shenyang, China, 110015
    - Withdrawn
    - Research Site
  - Wuhan, China, 430048
    - Not yet recruiting
    - Research Site
  - Xuzhou, China, 221000
    - Not yet recruiting
    - Research Site
  - Zhengzhou, China, 450000
    - Not yet recruiting
    - Research Site
Denmark
- - Aarhus, Denmark, 8200
    - Not yet recruiting
    - Research Site
  - Copenhagen, Denmark, 2100
    - Not yet recruiting
    - Research Site
  - Hellerup, Denmark, 2900
    - Not yet recruiting
    - Research Site
  - Odense C, Denmark, 5000
    - Not yet recruiting
    - Research Site
France
- - Angers, France, 49933
    - Not yet recruiting
    - Research Site
  - Brest, France, 29609
    - Not yet recruiting
    - Research Site
  - Bron, France, 69677
    - Not yet recruiting
    - Research Site
  - Montpellier, France, 34295
    - Not yet recruiting
    - Research Site
  - Nice, France, 6000
    - Not yet recruiting
    - Research Site
  - Paris, France, 75877
    - Not yet recruiting
    - Research Site
  - Rennes, France, 35033
    - Not yet recruiting
    - Research Site
  - Tours, France, 37000
    - Not yet recruiting
    - Research Site
Germany
- - Bonn, Germany, 53127
    - Not yet recruiting
    - Research Site
  - Essen, Germany, 45239
    - Not yet recruiting
    - Research Site
  - Freiburg im Breisgau, Germany, 79106
    - Not yet recruiting
    - Research Site
  - Fulda, Germany, 36043
    - Not yet recruiting
    - Research Site
  - Giessen, Germany, 35392
    - Not yet recruiting
    - Research Site
  - Hamburg, Germany, 20251
    - Not yet recruiting
    - Research Site
  - Hanover, Germany, 30459
    - Not yet recruiting
    - Research Site
  - Heidelberg, Germany, 69126
    - Not yet recruiting
    - Research Site
  - Hemer, Germany, 58675
    - Not yet recruiting
    - Research Site
  - Konstanz, Germany, 78464
    - Withdrawn
    - Research Site
  - Leipzig, Germany, 04103
    - Not yet recruiting
    - Research Site
  - Lübeck, Germany, 23538
    - Not yet recruiting
    - Research Site
  - Marburg, Germany, 35037
    - Not yet recruiting
    - Research Site
  - Munich, Germany, 81377
    - Not yet recruiting
    - Research Site
  - Stuttgart, Germany, 70376
    - Not yet recruiting
    - Research Site
  - Witten, Germany, 58452
    - Not yet recruiting
    - Research Site
  - Wuppertal-Barmen, Germany, 42283
    - Not yet recruiting
    - Research Site
Greece
- - Athens, Greece, 11527
    - Not yet recruiting
    - Research Site
  - Athens, Greece, 12462
    - Not yet recruiting
    - Research Site
  - Heraklion, Greece, 71110
    - Not yet recruiting
    - Research Site
  - Ioannina, Greece, 45500
    - Not yet recruiting
    - Research Site
  - Pátrai, Greece, 26500
    - Not yet recruiting
    - Research Site
  - Thessaloniki, Greece, 57010
    - Not yet recruiting
    - Research Site
Hungary
- - Budapest, Hungary, 1083
    - Not yet recruiting
    - Research Site
  - Budapest, Hungary, 1121
    - Not yet recruiting
    - Research Site
  - Debrecen, Hungary, 4032
    - Not yet recruiting
    - Research Site
  - Törökbálint, Hungary, 2045
    - Not yet recruiting
    - Research Site
Israel
- - Ashkelon, Israel, 78278
    - Not yet recruiting
    - Research Site
  - Jerusalem, Israel, 9103102
    - Not yet recruiting
    - Research Site
  - Kfar Saba, Israel, 4428164
    - Not yet recruiting
    - Research Site
  - Petah Tikva, Israel, 4941492
    - Not yet recruiting
    - Research Site
  - Rehovot, Israel, 76100
    - Not yet recruiting
    - Research Site
Italy
- - Foggia, Italy, 71100
    - Not yet recruiting
    - Research Site
  - Forlì, Italy, 47121
    - Not yet recruiting
    - Research Site
  - Modena, Italy, 41124
    - Not yet recruiting
    - Research Site
  - Monza, Italy, 20900
    - Not yet recruiting
    - Research Site
  - Pavia, Italy, 27100
    - Not yet recruiting
    - Research Site
  - Rozzano, Italy, 20089
    - Not yet recruiting
    - Research Site
  - Siena, Italy, 53100
    - Not yet recruiting
    - Research Site
  - Torino, Italy, 10126
    - Not yet recruiting
    - Research Site
Japan
- - Fukuoka, Japan, 810-8563
    - Not yet recruiting
    - Research Site
  - Hachioji-shi, Japan, 193-0998
    - Not yet recruiting
    - Research Site
  - Hamamatsu, Japan, 431-3192
    - Not yet recruiting
    - Research Site
  - Hiroshima, Japan, 734-8530
    - Not yet recruiting
    - Research Site
  - Kakogawa-shi, Japan, 675-8611
    - Not yet recruiting
    - Research Site
  - Kumagaya-shi, Japan, 360-0197
    - Not yet recruiting
    - Research Site
  - Kumamoto, Japan, 861-4193
    - Not yet recruiting
    - Research Site
  - Matsusaka-shi, Japan, 515-8544
    - Not yet recruiting
    - Research Site
  - Sakaishi, Japan, 591-8555
    - Not yet recruiting
    - Research Site
  - Sendai, Japan, 980-8574
    - Not yet recruiting
    - Research Site
  - Seto-shi, Japan, 489-8642
    - Not yet recruiting
    - Research Site
  - Shimotsuke-shi, Japan, 329-0498
    - Not yet recruiting
    - Research Site
  - Shinjuku-ku, Japan, 162-8655
    - Not yet recruiting
    - Research Site
  - Yokohama, Japan, 236-0051
    - Not yet recruiting
    - Research Site
  - Yokohama, Japan, 236-0037
    - Not yet recruiting
    - Research Site
Mexico
- - Benito Juárez, Mexico, 03330
    - Not yet recruiting
    - Research Site
  - Chihuahua City, Mexico, 31203
    - Not yet recruiting
    - Research Site
  - Coyocan, Mexico, 04330
    - Not yet recruiting
    - Research Site
  - León, Mexico, 37160
    - Not yet recruiting
    - Research Site
  - Monterrey, Mexico, 64460
    - Not yet recruiting
    - Research Site
  - Monterrey, Mexico, 64465
    - Not yet recruiting
    - Research Site
  - Mérida, Mexico, 97130
    - Not yet recruiting
    - Research Site
  - Oaxaca City, Mexico, 68000
    - Not yet recruiting
    - Research Site
  - Pachuca, Mexico, 42070
    - Not yet recruiting
    - Research Site
Poland
- - Bialystok, Poland, 15-044
    - Not yet recruiting
    - Research Site
  - Krakow, Poland, 31-202
    - Withdrawn
    - Research Site
  - Lodz, Poland, 90-153
    - Not yet recruiting
    - Research Site
  - Poznan, Poland, 60-569
    - Not yet recruiting
    - Research Site
  - Rzeszów, Poland, 35-205
    - Not yet recruiting
    - Research Site
  - Warsaw, Poland, 02-507
    - Not yet recruiting
    - Research Site
South Africa
- - Cape Town, South Africa, 7700
    - Not yet recruiting
    - Research Site
  - Durban, South Africa, 4001
    - Not yet recruiting
    - Research Site
  - Parktown West, South Africa, 2193
    - Not yet recruiting
    - Research Site
  - Somerset West, South Africa, 7130
    - Not yet recruiting
    - Research Site
South Korea
- - Seongnam-si, South Korea, 13620
    - Not yet recruiting
    - Research Site
  - Seoul, South Korea, 5505
    - Not yet recruiting
    - Research Site
  - Seoul, South Korea, 06351
    - Not yet recruiting
    - Research Site
  - Seoul, South Korea, 02841
    - Not yet recruiting
    - Research Site
  - Seoul, South Korea, 04401
    - Not yet recruiting
    - Research Site
Spain
- - Barcelona, Spain, 08036
    - Not yet recruiting
    - Research Site
  - Barcelona, Spain, 8025
    - Not yet recruiting
    - Research Site
  - L'Hospitalet de Llobregat, Spain, 08907
    - Not yet recruiting
    - Research Site
  - Madrid, Spain, 28006
    - Not yet recruiting
    - Research Site
  - Málaga, Spain, 29010
    - Not yet recruiting
    - Research Site
  - Valencia, Spain, 46010
    - Not yet recruiting
    - Research Site
Taiwan
- - Kaohsiung City, Taiwan, 80756
    - Not yet recruiting
    - Research Site
  - Kaohsiung City, Taiwan, 824
    - Not yet recruiting
    - Research Site
  - Taichung, Taiwan, 40705
    - Not yet recruiting
    - Research Site
  - Taipei, Taiwan, 11220
    - Not yet recruiting
    - Research Site
  - Taipei, Taiwan, 10002
    - Not yet recruiting
    - Research Site
  - Taipei, Taiwan, 11696
    - Not yet recruiting
    - Research Site
  - Taoyuan, Taiwan, 333
    - Not yet recruiting
    - Research Site
  - Yunlin, Taiwan, 640
    - Not yet recruiting
    - Research Site
United Kingdom
- - Bristol, United Kingdom, BS105NB
    - Not yet recruiting
    - Research Site
  - Cottingham, United Kingdom, HU16 5JQ
    - Not yet recruiting
    - Research Site
  - Edinburgh, United Kingdom, EH16 4SA
    - Not yet recruiting
    - Research Site
  - Exeter, United Kingdom, EX2 5DW
    - Not yet recruiting
    - Research Site
  - Liverpool, United Kingdom, L9 7AL
    - Not yet recruiting
    - Research Site
  - London, United Kingdom, SW3 6NP
    - Not yet recruiting
    - Research Site
United States
- Alabama
  - Birmingham, Alabama, United States, 35205
    - Not yet recruiting
    - Research Site
- Arizona
  - Phoenix, Arizona, United States, 85006
    - Not yet recruiting
    - Research Site
  - Phoenix, Arizona, United States, 85032
    - Not yet recruiting
    - Research Site
- California
  - Loma Linda, California, United States, 92350
    - Not yet recruiting
    - Research Site
  - Los Angeles, California, United States, 90033
    - Not yet recruiting
    - Research Site
  - Newport Beach, California, United States, 92663
    - Recruiting
    - Research Site
  - Sacramento, California, United States, 95817
    - Not yet recruiting
    - Research Site
  - Stanford, California, United States, 94305
    - Not yet recruiting
    - Research Site
- Colorado
  - Aurora, Colorado, United States, 80045
    - Not yet recruiting
    - Research Site
  - Denver, Colorado, United States, 80206
    - Not yet recruiting
    - Research Site
- Florida
  - Ocala, Florida, United States, 34470
    - Withdrawn
    - Research Site
  - Weston, Florida, United States, 33331
    - Not yet recruiting
    - Research Site
- Georgia
  - Atlanta, Georgia, United States, 30322
    - Not yet recruiting
    - Research Site
- Idaho
  - Boise, Idaho, United States, 83712
    - Not yet recruiting
    - Research Site
- Illinois
  - Champaign, Illinois, United States, 61820
    - Not yet recruiting
    - Research Site
  - Chicago, Illinois, United States, 60611
    - Not yet recruiting
    - Research Site
- Kansas
  - Kansas City, Kansas, United States, 66160
    - Not yet recruiting
    - Research Site
- Kentucky
  - Lexington, Kentucky, United States, 40536
    - Not yet recruiting
    - Research Site
- Maryland
  - Baltimore, Maryland, United States, 21201
    - Not yet recruiting
    - Research Site
- Massachusetts
  - Boston, Massachusetts, United States, 02114
    - Not yet recruiting
    - Research Site
- Michigan
  - Ann Arbor, Michigan, United States, 48109
    - Not yet recruiting
    - Research Site
  - Detroit, Michigan, United States, 48202
    - Not yet recruiting
    - Research Site
- New York
  - New York, New York, United States, 10029
    - Not yet recruiting
    - Research Site
  - New York, New York, United States, 10017
    - Not yet recruiting
    - Research Site
- North Carolina
  - Greensboro, North Carolina, United States, 27403
    - Not yet recruiting
    - Research Site
- Ohio
  - Cincinnati, Ohio, United States, 45267
    - Not yet recruiting
    - Research Site
- Oklahoma
  - Oklahoma City, Oklahoma, United States, 73117
    - Not yet recruiting
    - Research Site
- Pennsylvania
  - Bethlehem, Pennsylvania, United States, 18015
    - Not yet recruiting
    - Research Site
  - Philadelphia, Pennsylvania, United States, 19140
    - Not yet recruiting
    - Research Site
  - Philadelphia, Pennsylvania, United States, 19104
    - Not yet recruiting
    - Research Site
- South Carolina
  - Charleston, South Carolina, United States, 29425
    - Not yet recruiting
    - Research Site
- Texas
  - Dallas, Texas, United States, 75254
    - Not yet recruiting
    - Research Site
  - El Paso, Texas, United States, 79902
    - Recruiting
    - Research Site
  - Houston, Texas, United States, 77030
    - Not yet recruiting
    - Research Site
- Vermont
  - Burlington, Vermont, United States, 05401
    - Not yet recruiting
    - Research Site
- Virginia
  - Richmond, Virginia, United States, 23298
    - Not yet recruiting
    - Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Description

Inclusion Criteria:

Age ≥ 40 years
IPF diagnosis
Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
FVC ≥ 45% predicted of normal
DLCO corrected for hemoglobin ≥ 25% predicted of normal

Exclusion Criteria:

ILD other than IPF
The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
Acute exacerbation of IPF
Lower respiratory tract infection requiring treatment
Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
Heart failure
History of organ transplantation or is likely to receive lung transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Quadruple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo for AZD8965	Other: Placebo for AZD8965 Placebo for AZD8965
Experimental: AZD8965 low dose	Drug: AZD8965 low dose AZD8965 low dose
Experimental: AZD8965 medium dose	Drug: AZD8965 medium dose AZD8965 medium dose
Experimental: AZD8965 high dose	Drug: AZD8965 high dose AZD8965 high dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24 Time Frame: at Week 24	To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24	at Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Relationship between dose and clinical efficacy of AZD8965 at Week 24 Time Frame: Week 24	Change from baseline in FVC (in mL)	Week 24
Change from baseline in FVC at Week 24 Time Frame: Week 24	Change from baseline in % predicted FVC	Week 24
Change in rate of decline in FVC at Week 24 Time Frame: Week 24	Change in rate of decline in FVC (in mL/week)	Week 24
Number of participants with adverse events (AEs) Time Frame: Up to 25 weeks	Number of participants with AEs	Up to 25 weeks
Number of participants with serious adverse events (SAEs) Time Frame: Up to 25 weeks	Number of participants with SAEs	Up to 25 weeks
Number of participants with AEs leading to discontinuation Time Frame: Up to 25 weeks	Number of participants with AEs leading to discontinuation	Up to 25 weeks
Summary statistics to evaluate the PK of AZD8965 Time Frame: From baseline to Week 24	AZD8965 concentrations in plasma	From baseline to Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 11, 2026

Primary Completion (Estimated)

September 14, 2028

Study Completion (Estimated)

September 14, 2028

Study Registration Dates

First Submitted

May 5, 2026

First Submitted That Met QC Criteria

June 11, 2026

First Posted (Actual)

June 17, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 24, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

D6960C00005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing Access Criteria

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD Sharing Supporting Information Type

STUDY_PROTOCOL
SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Pulmonary Fibrosis (IPF)

First Affiliated Hospital of Wenzhou Medical University

Not yet recruiting

Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

CAR-DC for End-Stage IPF

Idiopathic Pulmonary Fibrosis(IPF)
Avalyn Pharma Inc.

Recruiting

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF (AURA-IPF)

Idiopathic Pulmonary Fibrosis (IPF)

Canada, Australia
Hubei Bio-Pharmaceutical Industrial Technological...

Not yet recruiting

A Phase I Study of HW241045 in Healthy Subjects

Idiopathic Pulmonary Fibrosis (IPF)

China
Beijing Tide Pharmaceutical Co., Ltd
China-Japan Friendship Hospital

Recruiting

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

China
Dragonboat Biopharmaceutical Company Limited

Recruiting

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

China
Regend Therapeutics

Not yet recruiting

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy

Idiopathic Pulmonary Fibrosis (IPF)

China
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Motivational Interviewing Program on the Self-Care in Idiopathic Pulmonary Fibrosis (MI-IPF)

Idiopathic Pulmonary Fibrosis (IPF)
Royal Brompton & Harefield NHS Foundation Trust

Recruiting

A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications (AF-BMC)

Idiopathic Pulmonary Fibrosis (IPF) | Progressive Pulmonary Fibrosis

United Kingdom

Clinical Trials on Placebo for AZD8965

AstraZeneca

Completed

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

Healthy Participants

United States
EnnovaBio Australia Pharmaceuticals Pty Ltd

Completed

A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects

Healthy

Australia
ZYUS Life Sciences Inc.
Novotech (Australia) Pty Limited; ZYUS Life Sciences Australia Pty Ltd

Completed

Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation (HOPE)

Healthy | Osteoarthritis

Australia
Theravance Biopharma

Completed

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Healthy

United States
Chong Kun Dang Pharmaceutical

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
Spero Therapeutics
Simbec Research

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Hanmi Pharmaceutical Company Limited

Completed

Trial to Evaluate the Efficacy and Safety of HCP1302

Hypertension | Erectile Dysfunction
Eli Lilly and Company
OPKO Health, Inc.

Completed

A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
AstraZeneca

Completed

A Study of MEDI7352 in Painful Osteoarthritis of the Knee

Chronic Pain

Germany, Sweden, United Kingdom
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. (ARGiNAUT)

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Estimated)

Phase

Contacts and Locations

Study Contact

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Estimated)

Study Completion (Estimated)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

IPD Sharing Time Frame

IPD Sharing Access Criteria

IPD Sharing Supporting Information Type

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trials on Placebo for AZD8965

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations